BRPI1010970A2 - solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento - Google Patents

solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento

Info

Publication number
BRPI1010970A2
BRPI1010970A2 BRPI1010970-6A BRPI1010970A BRPI1010970A2 BR PI1010970 A2 BRPI1010970 A2 BR PI1010970A2 BR PI1010970 A BRPI1010970 A BR PI1010970A BR PI1010970 A2 BRPI1010970 A2 BR PI1010970A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical solution
preparing
treating
pharmaceutical
solution
Prior art date
Application number
BRPI1010970-6A
Other languages
English (en)
Inventor
Sanjay Motwani Kumar
P. Isloor Sashikanth
Arora Vinod
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of BRPI1010970A2 publication Critical patent/BRPI1010970A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento a presente invenção refere-se a uma solução farmacêutica que compreende isotretinoina ou sais da mesma. a presente invenção se refere adicionalmente aos processos para preparar tais composições.
BRPI1010970-6A 2009-05-20 2010-05-20 solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento BRPI1010970A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1039DE2009 2009-05-20
IN1039/DEL/2009 2009-05-20
PCT/IB2010/052254 WO2010134047A2 (en) 2009-05-20 2010-05-20 Liquid dosage forms of isotretinoin

Publications (1)

Publication Number Publication Date
BRPI1010970A2 true BRPI1010970A2 (pt) 2019-04-09

Family

ID=54261167

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010970-6A BRPI1010970A2 (pt) 2009-05-20 2010-05-20 solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento

Country Status (8)

Country Link
US (2) US20120259013A1 (pt)
EP (1) EP2432553A2 (pt)
CN (1) CN102802729A (pt)
BR (1) BRPI1010970A2 (pt)
CA (1) CA2762391C (pt)
MX (1) MX2011012232A (pt)
SG (2) SG176096A1 (pt)
WO (1) WO2010134047A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2225600T3 (es) 2000-09-22 2005-03-16 Galephar M/F Composicion semi-solida de isotretinoina.
US9244235B2 (en) 2008-10-17 2016-01-26 Foro Energy, Inc. Systems and assemblies for transferring high power laser energy through a rotating junction
US9138786B2 (en) * 2008-10-17 2015-09-22 Foro Energy, Inc. High power laser pipeline tool and methods of use
EP2432453A2 (en) 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Topical retinoid solutions
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
EP2912193B1 (en) 2012-10-29 2018-08-29 Arizona Board of Regents on Behalf of University of Arizona Predictive markers for polyamine inhibitor cancer therapies
EP3148644A4 (en) 2014-05-29 2017-12-20 Sun Pharmaceutical Industries Ltd Oral pharmaceutical composition of isotretinoin
JP2017516794A (ja) * 2014-06-02 2017-06-22 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． 経口イソトレチノイン医薬組成物
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
AU2015294993A1 (en) 2014-07-31 2017-02-16 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
US9750711B2 (en) * 2014-10-01 2017-09-05 Sun Pharmaceutical Industries Limited Low dose oral pharmaceutical composition of isotretinoin
JP2018507910A (ja) 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
JP2018536707A (ja) 2015-10-30 2018-12-13 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤
KR20220082095A (ko) 2015-10-30 2022-06-16 팀버 파마슈티칼스 엘엘씨 이소트레티노인 제형 및 이의 용도 및 사용 방법
TWI917322B (zh) 2019-05-17 2026-03-11 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法
EP4236915A4 (en) * 2020-11-01 2024-10-23 Idrs Labs Pvt Ltd ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF ISOTRETINOIN
KR20250054055A (ko) 2022-07-01 2025-04-22 아크로테크 바이오파마 인코포레이티드. 이소트레티노인을 포함하는 제약 조성물 및 그의 제조 방법 및 용도
CN119033671B (zh) * 2024-09-05 2025-04-04 中南大学湘雅三医院 一种异维a酸油剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322438A (en) 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
ES2225600T3 (es) 2000-09-22 2005-03-16 Galephar M/F Composicion semi-solida de isotretinoina.
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20060241078A1 (en) * 2005-03-16 2006-10-26 Ahmed Salah U Pharmaceutical compositions comprising a contraceptive agent in solution and a teratogen
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof

Also Published As

Publication number Publication date
CA2762391A1 (en) 2010-11-25
SG176096A1 (en) 2011-12-29
SG2014011969A (en) 2014-09-26
WO2010134047A2 (en) 2010-11-25
CA2762391C (en) 2017-02-07
US20170165217A1 (en) 2017-06-15
EP2432553A2 (en) 2012-03-28
US20120259013A1 (en) 2012-10-11
MX2011012232A (es) 2012-04-10
CN102802729A (zh) 2012-11-28
WO2010134047A3 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
BR112017009701A2 (pt) composto e métodos para a preparação de um composto
BRPI0924136A8 (pt) Composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
BR112014003296A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
BR112014024180A2 (pt) copolímero de poliorganossiloxano linear, processo para a fabricação de copolímero de poliorganossiloxano linear, composições de poliorganossiloxano, emulsões aquosas, métodos de tratamento de superfície e processo para a fabricação de uma composição
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
BR112015006393A2 (pt) método para produzir um produto de tecido, produto de tecido produzido por um processo, e método de tratamento
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
BR112019006530A2 (pt) processo de purificação de óleo
ECSP14013211A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
BRPI0922774B8 (pt) composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.
BR112013031307A2 (pt) métodos para tratamento de material lignocelulósico
CY1123438T1 (el) Διαδικασια για παραγωγη και καθαρισμοανασυνδυασμενης λυσοσωμικης αλφα-μαννοσιδασης
BR112012020078A2 (pt) composição de tratamento de roupa método de tratamento de um produto têxtil de roupa
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
BR112015005633A2 (pt) composição farmacêutica tópica, processo para preparar uma composição farmacêutica tópica, método para prover ou facilitar a contracepção e método para tratar infecções retrovirais ou infecções bacterianas
BRPI1012713A2 (pt) processo para o pré-aquecimento de produto de recozimento em uma instalação de recozimento com cúpula.
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
BRPI1007433A2 (pt) método para tratar um substrato de carpete, composição de tratamento para conferir propriedades antimicrobianas duráveis a um carpete, e, produto de carpete.
BR112012019866A2 (pt) composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]